Kairos Pharma (KAPA)
Market Price (2/26/2026): $0.6 | Market Cap: $12.1 MilSector: Health Care | Industry: Biotechnology
Kairos Pharma (KAPA)
Market Price (2/26/2026): $0.6Market Cap: $12.1 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -146% | Penny stockMkt Price is 0.6 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 | |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.6 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -44% | ||
| High stock price volatilityVol 12M is 120% | ||
| Key risksKAPA key risks include [1] its heavy dependence on the successful outcome of clinical trials for its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -146% |
| Penny stockMkt Price is 0.6 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.6 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -44% |
| High stock price volatilityVol 12M is 120% |
| Key risksKAPA key risks include [1] its heavy dependence on the successful outcome of clinical trials for its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Kairos Pharma (KAPA) stock has lost about 45% since 10/31/2025 because of the following key factors:
1. Persistent Financial Losses and Lack of Revenue Generation: Kairos Pharma has consistently reported significant net losses and a continued absence of product revenues, raising concerns about its long-term financial viability. For the quarter ending September 30, 2025, the company reported a net income of -$1.4 million, contributing to a total net loss of -$5.06 million for the trailing 12 months ending September 30, 2025.
2. Unfavorable Market Reaction to Clinical Updates and Earnings: Despite a shareholder update on November 4, 2025, highlighting positive interim Phase 2 safety and efficacy results for ENV105 in metastatic prostate cancer, the stock experienced a notable negative impact of -14.12% on that day. While the Q3 2025 earnings, reported on November 14, 2025, surpassed EPS estimates, the market's focus likely remained on the company's underlying unprofitability and ongoing operational expenses, contributing to continued investor apprehension.
Show more
1. Persistent Financial Losses and Lack of Revenue Generation: Kairos Pharma has consistently reported significant net losses and a continued absence of product revenues, raising concerns about its long-term financial viability. For the quarter ending September 30, 2025, the company reported a net income of -$1.4 million, contributing to a total net loss of -$5.06 million for the trailing 12 months ending September 30, 2025.
2. Unfavorable Market Reaction to Clinical Updates and Earnings: Despite a shareholder update on November 4, 2025, highlighting positive interim Phase 2 safety and efficacy results for ENV105 in metastatic prostate cancer, the stock experienced a notable negative impact of -14.12% on that day. While the Q3 2025 earnings, reported on November 14, 2025, surpassed EPS estimates, the market's focus likely remained on the company's underlying unprofitability and ongoing operational expenses, contributing to continued investor apprehension.
Show more
Stock Movement Drivers
Fundamental Drivers
The -44.4% change in KAPA stock from 10/31/2025 to 2/25/2026 was primarily driven by a -14.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.13 | 0.63 | -44.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 17 | 20 | -14.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/25/2026| Return | Correlation | |
|---|---|---|
| KAPA | -44.4% | |
| Market (SPY) | 1.6% | 38.9% |
| Sector (XLV) | 9.4% | -2.9% |
Fundamental Drivers
The -30.2% change in KAPA stock from 7/31/2025 to 2/25/2026 was primarily driven by a -21.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.90 | 0.63 | -30.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 16 | 20 | -21.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/25/2026| Return | Correlation | |
|---|---|---|
| KAPA | -30.2% | |
| Market (SPY) | 10.0% | 27.3% |
| Sector (XLV) | 21.6% | 6.2% |
Fundamental Drivers
The -56.0% change in KAPA stock from 1/31/2025 to 2/25/2026 was primarily driven by a -46.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.43 | 0.63 | -56.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 11 | 20 | -46.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/25/2026| Return | Correlation | |
|---|---|---|
| KAPA | -56.0% | |
| Market (SPY) | 16.2% | 9.3% |
| Sector (XLV) | 8.9% | -3.9% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/25/2026| Return | Correlation | |
|---|---|---|
| KAPA | ||
| Market (SPY) | 76.9% | 6.2% |
| Sector (XLV) | 23.9% | 2.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| KAPA Return | - | - | - | -42% | -53% | -19% | -78% |
| Peers Return | 16% | -1% | 10% | 1% | 26% | 4% | 68% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| KAPA Win Rate | - | - | - | 25% | 25% | 0% | |
| Peers Win Rate | 52% | 55% | 48% | 55% | 55% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| KAPA Max Drawdown | - | - | - | -50% | -70% | -22% | |
| Peers Max Drawdown | -13% | -18% | -18% | -18% | -22% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EXEL, RCUS, REGN, AMGN, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/25/2026 (YTD)
How Low Can It Go
KAPA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to EXEL, RCUS, REGN, AMGN, BMY
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Kairos Pharma (KAPA)
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. Our mission is to advance our portfolio of innovative therapeutics to transform the way cancer is treated. We have leveraged molecular insights to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. “Checkpoints” refer to molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Our portfolio of seven drug candidates offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our key patents are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western United States, and Tracon Pharmaceuticals, Inc., a clinical stage public biopharmaceutical company based in California. The science underlying the patents was developed at Cedars-Sinai Medical Center and was licensed to us from this institution. The human immune system can tell the difference between normal cells in the body and those it sees as “foreign,” which allows it to focus an attack on the foreign cells while leaving the normal cells alone. To do this, our immune system uses checkpoints. Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system. We are developing small molecules that we believe can specifically target these central checkpoints. In addition, we are developing an activated T cell therapy that is designed to transform a patient’s T cells into killer activated T cells against cancerous stem cells. These activated T cells are induced to target several antigen targets on glioblastoma cancer stem cells, the initiators and propagators of glioblastoma tumors. In June 2021, Kairos acquired Enviro Therapeutics, Inc., a California corporation (“Enviro”), through a share exchange. Enviro’s shareholders exchanged 100% of the outstanding shares of Enviro for 6,000,000 shares of newly issued restricted shares of common stock of Kairos. After the closing, Enviro became a wholly owned subsidiary of Kairos. The acquisition allowed us to incorporate into our company Enviro’s advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Our drug candidate portfolio currently consists of a pipeline of seven drug candidates, including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse drug resistance that often results as a consequence of the use of cancer therapeutics. Our pipeline is summarized below: . Five pre-clinical or clinical-trial stage drug candidates developed by us and designed to target immune response, including KROS 101, 102, 201, 301, and 401, which are designed to reverse immunosuppression of T cells that is caused by cancer. - KROS 101 and 102 are small molecules that are agonist and antagonist for the GITR (glucocorticoid induced TNF-like receptor) ligand, which respectively promote and inhibit T cell growth and function. GITR is a checkpoint central to control the numbers of T cells of the immune system. These molecules are in the preclinical stage and are being developed for clinical trials. - KROS 201 is an autologous T cell therapy targeting cancer stem cells of glioblastoma. This therapy has received an IND from the FDA for clinical trial and is undergoing preparation for a Phase 1 clinical trial for patients with recurrent glioblastoma. - KROS 301 is a small molecule that targets the NF-ĸß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer. This molecule is in preclinical testing. - KROS 401 is a cyclic peptide which inhibits the IL-4 and IL-13 (cytokines that play a critical role in the suppression of T cells by macrophages at the site of the tumor) receptor and is designed to reverse the immunosuppression induced by macrophages in the tumor microenvironment. . Two therapeutic agents developed by our Enviro subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. - ENV 105 is an antibody that targets CD105 / Endoglin which is expressed in tumor cells and surrounding cells as the tumor becomes resistant to therapeutics in prostate cancer and lung cancer. This therapy is being tested in a randomized multicenter Phase 2 trial for prostate cancer and a Phase 1 trial in lung cancer, both of which began enrolling patients in September 2023. ENV 105 has received an IND from the FDA. - ENV 205 is an antibody that targets mitochondrial DNA which is elevated as patients become resistant to chemotherapies. This therapy is in preclinical testing. As of the date of this prospectus, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator. Kairos Pharma, Ltd. was originally incorporated on June 17, 2013 under the laws of the State of California as NanoGB13, Inc. We changed our name to “Kairos Pharma, Ltd.” on July 15, 2016. On May 10, 2023, we filed a certificate of conversion with the Secretary of State of the State of California and, on the same date, we also filed with the Secretary of State of the State of Delaware a certificate of conversion from a non-Delaware corporation to a Delaware corporation pursuant to the Delaware General Corporation Law. In addition, on May 10, 2023, we also filed a certificate of incorporation with the Secretary of State of the State of Delaware and became a Delaware corporation. Our registered corporate address is 2355 Westwood Blvd., #139, Los Angeles, California.
AI Analysis | Feedback
null
AI Analysis | Feedback
Kairos Pharma (symbol: KAPA) is a fictional company often used in case studies or educational materials and therefore does not have actual major products or services.AI Analysis | Feedback
As a public pharmaceutical company, Kairos Pharma (KAPA) would primarily sell its products to other companies rather than directly to individual consumers. The major customers for a pharmaceutical manufacturer are typically the large pharmaceutical wholesale distributors, which then supply drugs to pharmacies, hospitals, and other healthcare providers.
Based on the standard business model for a pharmaceutical company operating in major markets, Kairos Pharma's major customers would include:
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
These three companies are the largest pharmaceutical distributors in the United States and typically account for a significant portion of a pharmaceutical manufacturer's sales revenue, acting as the crucial intermediary in the drug supply chain.
AI Analysis | Feedback
null
AI Analysis | Feedback
John S. Yu, Chief Executive Officer & Chairman
Dr. John S. Yu founded Kairos Pharma on June 17, 2013. He is an accomplished neurosurgeon and immunotherapy expert, holding a BAS from Stanford, and an MD from Harvard Medical School and MIT. Dr. Yu also serves as a Professor of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars-Sinai Medical Center. He has developed numerous investigational drugs with the FDA (8 new drugs mentioned) and led multiple clinical trials. Prior to Kairos Pharma, he was the CEO and Chairman of AcTcell, and a Director of Enviro Therapeutics. His career has focused on groundbreaking research in cancer therapeutics, and he holds numerous patents for immunotherapies and nanotechnologies from his NIH-funded laboratory.
Doug Samuelson, Chief Financial Officer
Doug Samuelson brings over 25 years of experience in finance, having served as CFO for various biopharma companies. He is a CPA in the State of California. His previous roles include CFO of Wellness Center USA, CFO of AdvaVet, Inc., CFO of Solis Tek, Inc., and Director of Accounting of Second Sight Medical Products, Inc. His expertise encompasses financial management and regulatory compliance.
Neil Bhowmick, Chief Scientific Officer & President, Enviro Therapeutics
Dr. Neil Bhowmick possesses over 20 years of extensive biochemistry expertise. He has filed and prosecuted patents for therapeutics and devices, authored 110 peer-reviewed publications, and led foundational and preclinical cancer research. He holds 6 patents for biomarker detection platforms and stromal targeted therapeutics, including ENV105 and ENV205. Dr. Bhowmick's background includes a fellowship at Vanderbilt University Medical Center and serving as Research Director at Oppenheimer Urologic Reference Laboratory (OURLab). He has also been a consultant at Xencor Inc. and Tracon Pharma.
Ramchandran Murali, VP, Research and Development
Dr. Ramchandran Murali is an immunologist and molecular engineer recognized for his work in developing pharmacological agents to counter immune suppression in cancer. His extensive research background is instrumental in advancing Kairos Pharma's innovative drug pipeline. He is also a Professor of Biomedical Sciences and Research in Immunology at Penn/Cedars-Sinai Medical Center, and a leading expert in X-ray crystallography, biophysical, biochemical, and immunology fields, having made significant advances in molecular engineering and cell surface receptors. He has developed numerous technologies that reverse key mechanisms of immune suppression of cancer.
AI Analysis | Feedback
Here are the key risks to Kairos Pharma's business:- Clinical Trial and Drug Development Risk: As a clinical-stage biopharmaceutical company, Kairos Pharma's success is heavily reliant on the successful outcome of its ongoing clinical trials for its lead candidate, ENV-105. ENV-105 is currently in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer. There is no guarantee that the data from these trials will be positive or that the drug will effectively overcome drug resistance as intended. Failure to achieve positive results in these trials, or any future trials, could significantly impact the company's viability and future prospects.
- Financial Position and Need for Future Funding: Kairos Pharma is currently unprofitable, with losses increasing over the past five years. Developing new pharmaceutical products through clinical trials is a capital-intensive process. While the company has a cash balance, it may need to raise additional funds to continue its research and development efforts, especially if clinical trials are extended or further studies become necessary. The ability to secure sufficient future funding is critical and is often contingent on positive clinical trial results and favorable market conditions.
- Regulatory Approval Risk: Even if clinical trials for ENV-105 yield positive results, Kairos Pharma faces significant regulatory hurdles. The company must obtain extensive regulatory approvals from bodies such as the U.S. Food and Drug Administration (FDA) before it can commercialize its drug candidates. The regulatory approval process is complex, lengthy, and subject to unpredictable changes, and there is no assurance that ENV-105 will ultimately receive the necessary approvals.
AI Analysis | Feedback
null
AI Analysis | Feedback
Kairos Pharma (KAPA) is a clinical-stage biopharmaceutical company focusing on oncology therapeutics. The addressable markets for their main product candidates are as follows:
- ENV105 (Castrate-Resistant Prostate Cancer): The global castrate-resistant prostate cancer (CRPC) market was estimated at approximately USD 12.95 billion in 2024 and is projected to reach about USD 21.44 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 8.7% from 2025 to 2030. The metastatic CRPC therapeutics market specifically was valued at USD 16.46 billion in 2024 and is projected to grow to USD 87.19 billion by 2032 with a CAGR of 22.5% during the forecast period.
- ENV105 (Lung Cancer): The global lung cancer therapeutics market size was approximately USD 35.37 billion in 2025 and is forecasted to reach around USD 71.30 billion by 2034, exhibiting a CAGR of 8.10% from 2025 to 2034. Another estimate places the global lung cancer market at USD 38.4 billion in 2025, growing to USD 95.1 billion in 2034 with a CAGR of 10.6%.
- KROS201 (Glioblastoma): The global glioblastoma treatment market was valued at USD 3.05 billion in 2024 and is expected to reach USD 6.22 billion by 2032, at a CAGR of 9.30% during the forecast period. Other projections estimate the global glioblastoma multiforme treatment market to grow from USD 3.72 billion in 2024 to USD 7.87 billion by 2033 with a CAGR of 8.68%.
- KROS401 (Triple Negative Breast Cancer): The global triple negative breast cancer (TNBC) market was valued at USD 1.06 billion in 2024 and is expected to reach USD 1.63 billion by 2032, growing at a CAGR of 5.50% from 2025 to 2032. Another report indicates the global TNBC market size to be USD 1.15 billion in 2025, projected to reach USD 1.41 billion by 2029 with a CAGR of 5.1%.
- KROS101, KROS102, KROS301: Specific addressable market sizes for these individual product candidates beyond the general oncology or immunotherapy market are not available. However, the broader global cancer immunotherapy market was valued at USD 226.38 billion in 2024 and is projected to reach USD 443.17 billion by 2030, growing at a CAGR of 11.90%. The global immunotherapy drugs market, which encompasses these types of therapies, was estimated at USD 257.6 billion in 2024 and is projected to reach USD 486.36 billion by 2030, growing at a CAGR of 11.2%.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Kairos Pharma (KAPA)
Over the next 2-3 years, Kairos Pharma's potential for revenue growth is primarily linked to the successful advancement and commercialization of its clinical-stage pipeline. The key expected drivers include:
- Advancement and Commercialization of ENV105: Kairos Pharma's lead therapeutic candidate, ENV105, an antibody targeting CD105, is currently undergoing Phase 2 clinical trials for advanced metastatic prostate cancer and Phase 1 trials for lung cancer. The company has reported positive interim safety and efficacy results from the Phase 2 prostate cancer trial. Successful progression through clinical development, regulatory approval, and subsequent market launch of ENV105 would be a significant driver of future product revenue.
- Development and Launch of KROS101: The company has presented promising new data on KROS101, an investigational small molecule GITR ligand agonist, as a potential cancer immunotherapy. If KROS101 successfully navigates clinical trials and gains regulatory approval, its commercialization would introduce a new product and revenue stream for Kairos Pharma.
- Expansion into New Cancer Indications: Kairos Pharma's strategy involves leveraging its lead candidate, ENV105, to address multiple cancer types by reversing drug resistance and restoring the effectiveness of standard therapies. Successful clinical trials and subsequent approvals for additional cancer indications beyond prostate and lung cancer would expand the addressable market and contribute to revenue growth.
- Strategic Partnerships and Collaborations: Recent partnerships are anticipated to enhance Kairos Pharma's innovation in pharmaceutical products and bolster its research and development capabilities. These collaborations could generate revenue through various mechanisms, such as upfront payments, milestone payments tied to development progress, and royalty streams from licensed assets.
AI Analysis | Feedback
Share Issuance
- On September 16, 2024, Kairos Pharma completed its Initial Public Offering (IPO), issuing 1.55 million common shares at an offering price of $4.00 per share, raising gross proceeds of $6.2 million.
- In January 2025, the company raised an additional $3.5 million through a Private Investment in Public Equity (PIPE) transaction by selling 2.5 million common units at $1.40 each, along with warrants.
- The total number of shares outstanding for Kairos Pharma increased by 35.56% in one year.
Inbound Investments
- The company's Phase 2 clinical trial for ENV105 in prostate cancer is partially funded by a $3.2 million NIH grant.
- Kairos Pharma raised $3.5 million in January 2025 via a Private Investment in Public Equity (PIPE) transaction from accredited investors.
- In November 2025, Kairos Pharma received a Department of Defense grant to support the study of its lead candidate ENV105 for preventing drug resistance in lung cancer, and another grant for research of ENV205 to treat chemotherapy drug resistance and cachexia.
Capital Expenditures
- Proceeds from the IPO and subsequent financings are primarily allocated to advancing clinical trials, including Phase 1 and 2 trials for its lead candidate ENV-105 in lung and prostate cancer.
- The company's operational expenses, largely driven by research and development as a clinical-stage biopharmaceutical company, are projected to be $3.7 million for 2025 and $7.2 million for 2026.
- Kairos Pharma reported a quarterly burn rate of approximately $0.6 million.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Day 8 of Gains Streak for Kairos Pharma Stock with 67% Return (vs. 30% YTD) [9/9/2025] | 09/10/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to KAPA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 53.02 |
| Mkt Cap | 46.4 |
| Rev LTM | 8,332 |
| Op Inc LTM | 2,297 |
| FCF LTM | 2,305 |
| FCF 3Y Avg | 2,103 |
| CFO LTM | 2,932 |
| CFO 3Y Avg | 2,652 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.0% |
| Rev Chg 3Y Avg | 11.9% |
| Rev Chg Q | 2.5% |
| QoQ Delta Rev Chg LTM | 0.7% |
| Op Mgn LTM | 25.8% |
| Op Mgn 3Y Avg | 24.8% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 29.4% |
| CFO/Rev 3Y Avg | 30.5% |
| FCF/Rev LTM | 26.3% |
| FCF/Rev 3Y Avg | 26.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 46.4 |
| P/S | 5.6 |
| P/EBIT | 12.2 |
| P/E | 16.5 |
| P/CFO | 11.1 |
| Total Yield | 6.1% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | 5.4% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.8% |
| 3M Rtn | 0.6% |
| 6M Rtn | 33.0% |
| 12M Rtn | 15.9% |
| 3Y Rtn | 7.5% |
| 1M Excs Rtn | 2.8% |
| 3M Excs Rtn | -0.6% |
| 6M Excs Rtn | 26.4% |
| 12M Excs Rtn | -0.2% |
| 3Y Excs Rtn | -67.7% |
Price Behavior
Price Behavior
| Market Price | $0.63 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 09/16/2024 | |
| Distance from 52W High | -68.1% | |
| 50 Days | 200 Days | |
| DMA Price | $0.72 | $1.24 |
| DMA Trend | down | down |
| Distance from DMA | -12.7% | -49.3% |
| 3M | 1YR | |
| Volatility | 82.7% | 119.9% |
| Downside Capture | 231.94 | 41.82 |
| Upside Capture | 102.73 | -25.02 |
| Correlation (SPY) | 21.4% | 8.4% |
KAPA Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.60 | 0.22 | 2.76 | 2.13 | 0.49 | 0.60 |
| Up Beta | -3.32 | -2.61 | 4.30 | 3.31 | 0.50 | 0.24 |
| Down Beta | 0.60 | 1.65 | 4.28 | 4.58 | 1.20 | 1.21 |
| Up Capture | -284% | -113% | -17% | 2% | -21% | -4% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 15 | 22 | 54 | 103 | 138 |
| Down Capture | -280% | 113% | 272% | 118% | 56% | 53% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 25 | 38 | 67 | 142 | 196 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KAPA | |
|---|---|---|---|---|
| KAPA | -44.7% | 119.9% | 0.00 | - |
| Sector ETF (XLV) | 8.4% | 17.3% | 0.31 | -4.5% |
| Equity (SPY) | 17.2% | 19.4% | 0.69 | 8.6% |
| Gold (GLD) | 75.4% | 25.7% | 2.16 | 0.9% |
| Commodities (DBC) | 9.7% | 16.9% | 0.38 | -0.6% |
| Real Estate (VNQ) | 7.2% | 16.6% | 0.25 | -0.3% |
| Bitcoin (BTCUSD) | -27.7% | 44.9% | -0.59 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KAPA | |
|---|---|---|---|---|
| KAPA | -24.0% | 163.6% | 0.03 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 2.8% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 6.1% |
| Gold (GLD) | 23.4% | 17.1% | 1.12 | -3.6% |
| Commodities (DBC) | 10.7% | 19.0% | 0.45 | -0.7% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.18 | 3.0% |
| Bitcoin (BTCUSD) | 5.1% | 57.1% | 0.31 | 3.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KAPA | |
|---|---|---|---|---|
| KAPA | -12.8% | 163.6% | 0.03 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 2.8% |
| Equity (SPY) | 15.5% | 17.9% | 0.75 | 6.1% |
| Gold (GLD) | 15.2% | 15.6% | 0.81 | -3.6% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | -0.7% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | 3.0% |
| Bitcoin (BTCUSD) | 66.0% | 66.7% | 1.05 | 3.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.